SBTX Silverback Therapeutics

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by .

In addition, ARS Pharma Management will be participating at several upcoming investor conferences:

  • 10th Annual Oppenheimer Emerging Growth Conference: February 25, 2026

  • Leerink Conference: March 11, 2026

    A live webcast of the presentation will be available .
  • 38th Annual ROTH Conference: March 22, 2026

To access the webcast and slides, please visit the page in the “Investors & Media” section of the Company’s . A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit .

ARS Investor Contact:

Justin Chakma

ARS Pharmaceuticals

ARS Media Contact:

Christy Curran

Sam Brown Inc.

615.414.8668



EN
23/02/2026

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

neffy® (epinephrine nasal spray) Approved in Canada as the First and O...

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer of 2026 SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against al...

April 15, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement Fr...

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label Children were previously required to weigh ≥33 lbs. and

March 27, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financia...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS ...

March 9, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Four...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 fi...

February 23, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clini...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by mor...

February 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch